Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Prior Auth Criteria — Part D | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Medicare Part D Prior Authorization Criteria — 2026 Formulary (Medicare C‑SNP Part D)

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization requirements for drugs on Independent Health's 2026 Medicare Advantage C‑SNP Part D formulary describing clinical, prescriber, age, and documentation criteria for coverage decisions.

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Part D Prior Authorization Criteria — 2026 Formulary (Medicare C‑SNP Part D)
    Policy CodePolicy N/A
    Change TypeAnnual/maintenance update — no material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing or dispensing any drug listed with 'PA' to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare C-SNP Part Dapplicable formulary
    1 yeartypical coverage duration
    ~70+listed products (excerpt)
    6 monthsinitial shorter duration examples
    frequentspecialty prescriber restrictions

    Product-Specific Coverage Criteria

    ACTIMMUNE (example)

    Covered when ALL of the following are met:

    ACTIMMUNE: Diagnosis of covered use documented; prescribed for an FDA‑approved indication; coverage duration 1 year

    May require description to determine Medicare Part B vs Part D coverage (self‑administration vs provider administration).

    Pulmonary Hypertension (PAH/CTEPH) Criteria

    Covered when ALL of the following are met:

    PAH agents: Diagnosis confirmed by right heart catheterization with mean pulmonary arterial pressure >20 mm Hg at rest and pulmonary arterial wedge pressure ≤15 mm Hg; for PAH (WHO Group 1) PVR >2 Woods units; for CTEPH (WHO Group 4) PVR >3 Woods units plus imaging evidence of chronic pulmonary embolism and attestation disease is inoperable or persistent/recurrentmPAP >20 mm Hg; PAWP ≤15 mm Hg; PVR >2 (PAH) or >3 (CTEPH) Woods units

    Submit WHO group classification, creatinine clearance, pregnancy status; prescriber specialty restrictions apply; initial PAH authorization requires trial/failure or intolerance to both a PDE5 inhibitor (sildenafil or tadalafil) and an ERA (ambrisentan or bosentan).

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Part D Prior Authorization Criteria — 2026 Formulary (Medicare C‑SNP Part D)
    Policy CodePolicy N/A
    Change TypeAnnual/maintenance update — no material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before prescribing or dispensing any drug listed with 'PA' to ensure coverage.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaPrior Authorization, Documentation & Denial RisksCodes, Thresholds, and Key Clinical ValuesInitial Authorization / Start-of-Therapy RulesReauthorization / Ongoing Use RequirementsStep Therapy & Prior-Use RequirementsCoverage by Site of Care (Part B vs Part D Considerations)Policy Scope and Background

    Biologic initiation and reauthorization

    Covered when ALL of the following are met:

    Most biologics (managed group): Diagnosis of covered use; baseline latent tuberculosis screening (PPD or IGRA) completed prior to initiation (except where policy specifies exceptions); prescriber specialty restriction met where required; coverage duration typically 1 year

    For initial authorization many biologics require trial and failure of ≥2 preferred agents where possible; if TB test positive, treat latent TB prior to initiation; annual TB screening/chest X‑ray may be required for ongoing exposure risk.

    Initial authorization prerequisites: Provider must submit current and prior therapies, indication‑specific objective tests where applicable (e.g., FEV1 and blood eosinophils for asthma; endoscopy/biopsy for EoE), and attest continuation of background therapies when required

    Initial authorization typically 6 months for some products (per product details) then 1 year; reauthorization requires documentation of clinical benefit or maintenance of previously achieved benefit.

    AUSTEDO criteria

    Covered when ALL of the following are met:

    AUSTEDO: Diagnosis of covered use; exclude congenital long QT or history of arrhythmia with prolonged QT, avoid coadministration with MAOIs, evaluate for active suicidal ideation or untreated depression, assess hepatic impairment (Child‑Pugh); prescriber restricted to neurology or psychiatry; coverage duration 1 year

    For Huntington chorea initial authorization requires prior trial and failure or intolerance to tetrabenazine; annual reauthorization for tardive dyskinesia requires documentation of symptomatic improvement or maintenance.

    BYLVAY criteria

    Covered when ALL of the following are met:

    BYLVAY: Diagnosis confirmed by appropriate molecular genetic testing and documentation of cholestasis (one of: total serum bile acids above age‑adjusted ULN; increased conjugated bilirubin; GGT above age‑adjusted ULN; fat‑soluble vitamin deficiency or intractable pruritus attributable to liver disease); attestation drug‑induced pruritus ruled out; prescriber restricted to gastroenterology/hepatology

    Initial coverage initially 6 months then 1 year; initial authorization requires trial/failure or intolerance to at least two agents among cholestyramine, naltrexone, rifampin, and ursodiol; first reauthorization requires attestation of symptomatic improvement and LFTs including bilirubin.

    Cablivi criteria

    Covered when ALL of the following are met:

    Cablivi (caplacizumab): Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP); confirmation drug will be given with plasma exchange and appropriate immunosuppressive therapy; patient age ≥12 years; prescriber restricted to cardiology, hematology, or immunology

    Coverage duration 3 months; if request is not for first use submit previous aTTP recurrences on caplacizumab — do not authorize if patient had >2 recurrences while on therapy.

    Cholestasis-related therapy criteria

    Covered when ALL of the following are met:

    Cholestasis‑related product (initial): Diagnosis confirmed by molecular genetic testing and documentation of cholestasis as defined by one of: (1) total serum bile acid > age‑adjusted ULN; (2) increased conjugated bilirubin; (3) GGT > age‑adjusted ULN; or (4) fat‑soluble vitamin deficiency or intractable pruritus attributable to liver disease; attestation drug‑induced pruritus ruled out; submission of prior/current therapies used to treat the condition

    Initial authorization requires trial/failure/intolerance to at least two of cholestyramine, naltrexone, rifampin, or ursodiol; prescriber restricted to gastroenterology/hepatology; initial coverage 6 months then 1 year; first reauthorization requires improvement in pruritus and LFTs including bilirubin; subsequent annual reauthorizations require maintenance of clinical benefit and LFTs.

    Caplacizumab (CABLIVI) criteria

    Covered when ALL of the following are met:

    Caplacizumab initial: Diagnosis of covered use (aTTP); drug to be administered with plasma exchange and immunosuppression; patient age ≥12; prescriber specialty restriction met (cardiology/hematology/immunology)

    If request is not first use, submit prior aTTP recurrences while on caplacizumab; coverage will not be authorized if >2 recurrences occurred while on therapy; coverage duration 3 months.

    CAMZYOS criteria

    Covered when ALL of the following are met:

    CAMZYOS (mavacamten): Diagnosis with documentation of exertional symptoms consistent with NYHA class II or III and LVOT gradient ≥50 mm Hg (rest, Valsalva, or after exercise); LV wall thickness ≥15 mm (≥13 mm if familial); submission of current LVEF and pregnancy status; patient age ≥18; prescriber restricted to cardiologyLVOT gradient ≥50 mm Hg; LV wall thickness ≥15 mm (≥13 mm if familial)

    Initial authorization requires prior trial and failure or intolerance to both a beta‑blocker and a non‑DHP calcium channel blocker; annual reauthorization requires confirmation of symptomatic/clinical improvement or maintenance.

    CFTR modulators criteria

    Covered when ALL of the following are met:

    CFTR modulators: Diagnosis of cystic fibrosis and submission of CFTR mutation testing confirming mutation(s) responsive per the specific drug's prescribing information (Kalydeco, Orkambi, Symdeko, Trikafta); prescriber restricted to pulmonology

    Coverage duration 1 year; Trikafta has exclusion for severe hepatic impairment; submit mutation test per product labeling or in‑vitro responsiveness data.

    Migraine biologics (Emgality, Aimovig, others) criteria

    Covered when ALL of the following are met:

    Acute migraine (CGRP agents): Documentation of trial and failure of one triptan or documented contraindication to triptans; age per product labeling

    Coverage duration for acute migraine 1 year.

    Preventive migraine (CGRP biologics): For episodic migraine prevention document baseline headache days/month (<15 days/month for episodic prevention); Emgality for prevention requires prior failure or intolerance to Aimovig; initial prevention authorization 3 months then 1 year; reauthorization requires on‑treatment headache days showing improvement from baseline and annual maintenance documentation<15 headache days/month for episodic prevention

    Prescriber restrictions may apply.

    DOPTELET criteria

    Covered when ALL of the following are met:

    Procedural thrombocytopenia indication: For patients with chronic liver disease scheduled for a procedure: submission of platelet count <50 x10^9/L; coverage for procedure period (typically 5 days)platelet count <50 x10^9/L

    Prescriber restrictions apply; exclude if platelet normalized before procedure.

    ITP indication: For immune thrombocytopenia (ITP): submission of platelet count <30 x10^9/L or <50 x10^9/L with symptomatic bleeding; documentation of prior therapies tried and failed and splenectomy status; initial authorization 2 months then 1 yearplatelet count <30 x10^9/L or <50 x10^9/L with symptomatic bleeding

    Initial authorization requires failure/intolerance to ≥2 ITP therapies from different classes; first reauthorization requires platelet improvement ≥50 x10^9/L after ≥4 weeks on max tolerated dose.

    Dupilumab Initial and Reauthorization Criteria

    Covered when ALL of the following are met:

    Dupilumab initial authorization: Indication‑specific diagnostic confirmation required; prerequisite or concomitant therapies per indication (e.g., failed moderate topical corticosteroid ≥4 weeks for AD; GINA‑recommended maximally tolerated ICS+LABA+LAMA for asthma; intranasal corticosteroid trial for CRSwNP; biopsy‑confirmed EoE); provider attestation that required background therapy will be continued when specified

    Initial coverage initially 6 months then 1 year; reauthorization requires documentation of clinical benefit or maintenance of previously achieved benefit and updated objective tests as indicated (e.g., FEV1, blood eosinophils, endoscopy/biopsy for EoE).

    Eltrombopag Criteria

    Covered when ALL of the following are met:

    Eltrombopag initial authorization: Diagnosis of covered use and submission of platelet count meeting indication‑specific thresholds (ITP, chronic hepatitis C, aplastic anemia); documentation of prior therapies tried and failed for ITP or AA; prescriber specialty restriction metITP: <30 x10^9/L or <50 x10^9/L with increased bleeding risk; chronic hepatitis C: <75 x10^9/L; AA: <30 x10^9/L

    Coverage duration varies by indication (e.g., ITP initially 12 weeks then 1 year; AA 6 months); reauthorization requires updated platelet count showing improvement and maintenance of clinical benefit.

    ENSACOVE Criteria

    Covered when ALL of the following are met:

    ENSACOVE authorization: Confirmed ALK‑positive tumor by testing; attestation patient has not previously received an ALK inhibitor; prescriber restricted to oncology; submission of pregnancy status for females of childbearing potential

    Exclusion for prior ALK‑inhibitor use and for coadministration with moderate/strong CYP3A4 or P‑gp inhibitors/inducers or in severe hepatic impairment; coverage duration 1 year.

    EOHILIA Criteria

    Covered when ALL of the following are met:

    EOHILIA authorization (EoE): Upper endoscopy with biopsy demonstrating ≥15 eosinophils per high‑power field (or ≥60 eos/mm2) and documentation of relevant symptoms (e.g., dysphagia, food impaction); documented failure of an 8‑week proton pump inhibitor trial; prescriber restricted to allergy, gastroenterology, immunology, or ENT>=15 eos/HPF or 60 eos/mm2

    Coverage duration 12 weeks; maximum one 12‑week course every 365 days; age ≥11 years.

    FABHALTA Criteria

    Covered when ALL of the following are met:

    FABHALTA indications: Indication‑specific diagnostic confirmation required: for PNH submit flow cytometry confirming PNH clones and documentation of inadequate response or intolerance to eculizumab or ravulizumab; for IgAN submit UPCR ≥1.5 g/g and documentation of failure/intolerance to maximally tolerated ACE inhibitor/ARB and additional agents as specified; for C3G submit kidney biopsy confirming diagnosis and required concomitant therapiessee product thresholds (e.g., UPCR >=1.5 g/g for IgAN)

    Prescriber restricted to hematology/nephrology; coverage 1 year; reauthorization requires documentation of clinical response or maintenance of benefit.

    FILSPARI Criteria

    Covered when ALL of the following are met:

    FILSPARI authorization: Biopsy‑confirmed primary IgA nephropathy; submission of 24‑hour urine protein ≥0.5 g/day or UPCR ≥0.8 g/g; eGFR and liver function testing submitted; prescriber restricted to immunology/nephrology; documentation of prior use of maximally‑tolerated ACE inhibitor or ARB (or intolerance)UPCR >=0.8 g/g or 24‑hour protein >=0.5 g/day

    Coverage duration 1 year; annual reauthorization requires clinically relevant response (stabilization or improvement in UPCR).

    Diabetes Agents Criteria

    Covered when ALL of the following are met:

    GLP‑1 agents authorization: Documented diagnosis of type 2 diabetes by medical record, ICD‑10, or laboratory criteria (A1c, fasting plasma glucose, 2‑hour OGTT, or random plasma glucose with classic signs/symptoms); age consistent with product labeling; prescriber specialty as required

    Coverage duration 1 year; off‑label use for weight management excluded from Medicare Part D.

    Norditropin Criteria

    Covered when ALL of the following are met:

    Norditropin authorization: Diagnosis of growth failure with submitted documentation (IGF‑1, height, weight), creatinine clearance (or serum creatinine), fasting glucose, and bone age if applicable; prescriber restricted to endocrinology or nephrology

    Coverage duration 1 year; annual reauthorization requires updated labs and evidence of clinical improvement or maintenance.

    GLP-1 agents (Mounjaro, Ozempic, Rybelsus, etc.)

    Covered when ALL of the following are met:

    GLP‑1 initial coverage: Diagnosis of type 2 diabetes confirmed by medical record, ICD‑10, or laboratory criteria; age consistent with prescribing information; prescriber restrictions where applicable

    Coverage duration 1 year; off‑label weight management use excluded under Medicare Part D.

    Hereditary angioedema agents (HAEGARDA, TAKHZYRO)

    Covered when ALL of the following are met:

    HAE prophylaxis agents: Diagnosis of hereditary angioedema and documentation that prophylactic therapy is medically necessary (disease activity, attack frequency, impact on quality of life); prescriber restricted to allergy, dermatology, hematology, or immunology; age per product labeling

    Coverage duration 1 year; requests for acute (on‑demand) HAE therapy may be excluded for certain products as specified.

    Product-specific coverage summaries

    Covered when ALL of the following are met (per‑product summaries):

    Oncology/hematology agents: Diagnosis of covered use and submission of required genetic/tumor testing or prior therapy documentation as specified per product (e.g., BRCA, FLT3, ALK, FGFR testing); prescriber specialty restriction to oncology/hematology where required; submission of baseline labs and safety monitoring data when indicated

    Coverage typically 1 year; many products exclude coadministration with strong/moderate CYP3A4 inducers or QT‑prolonging drugs and require pregnancy status for females of childbearing potential.

    Immunoglobulin products: Diagnosis of covered use; submission of indication‑specific labs (e.g., platelet count for ITP, IgG <600 mg/dL for CLL); reauthorization requires demonstration of clinical benefit or maintenance

    Acute conditions: 3 months; chronic conditions: 1 year; IV formulations administered at home for primary immune deficiency may be Part B.

    Antifungal coverage (example)

    Covered when ALL of the following are met:

    Antifungal (example): Diagnosis of culture‑proven systemic blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis; submission of baseline ALT, AST, total bilirubin, alkaline phosphatase, prothrombin time/INR; prescriber attestation benefits outweigh risks

    Coverage duration 6 months; excludes treatment of fungal meningitis or infections of skin or nails.

    Oncology targeted therapy (KOMZIFTI)

    Covered when ALL of the following are met:

    KOMZIFTI (oncology targeted therapy): Diagnosis consistent with covered use and submission of genetic tumor testing confirming HR‑positive, HER2‑negative primary tumor where required; submission of QTcF and serum potassium/magnesium within prior 6 months; pregnancy status for females of childbearing potential; attestation regimen includes an aromatase inhibitor or fulvestrantage ≥18

    Prescriber restricted to oncology; exclusions include congenital long QT, QTcF ≥450 msec, uncorrected electrolyte abnormalities, strong CYP3A4 inducers or QT‑prolonging drugs; coverage duration 1 year.

    Lapatinib coverage

    Covered when ALL of the following are met:

    Lapatinib authorization: Diagnosis of HER2‑positive disease with required baseline testing; submission of baseline potassium and magnesium; pregnancy status for females of childbearing potential; attestation concomitant use with capecitabine or letrozole as indicatedage ≥18

    Prescriber restricted to oncology; for lapatinib with capecitabine prior therapy with an anthracycline, a taxane, and trastuzumab required; coverage 1 year.

    Sickle cell therapy (l-glutamine)

    Covered when ALL of the following are met:

    L‑glutamine (sickle cell): Diagnosis of sickle cell disease; submission of current/previous therapies and documentation that patient tried and failed or had intolerance/contraindication to hydroxyurea prior to initiation

    Prescriber restricted to hematology; coverage duration 1 year.

    PARP inhibitor coverage

    Covered when ALL of the following are met:

    PARP inhibitors (e.g., olaparib): Diagnosis of covered indication with required genetic testing (BRCA or homologous recombination deficiency or other HRR mutations as indicated by indication); submission of prior therapy history and pregnancy status for females of childbearing potential; prescriber specialty restriction met

    Coverage duration 1 year; coadministration with moderate/strong CYP3A inducers may be exclusionary.

    Initial authorization (product-group example)

    Covered with prior authorization when ALL of the following are met:

    General initial authorization: Diagnosis corresponds to an FDA‑approved indication for the product; prescriber specialty restriction met (when required); required diagnostic/lab testing submitted as specified per product; no exclusion conditions present

    See product‑specific nodes for lab and prior therapy requirements; reauthorization requires documentation of clinical benefit or maintenance of prior benefit.

    Biomarker-confirmed indications

    Covered when ALL of the following are met:

    Biomarker/diagnostic‑confirmed indications: Submission of test confirming the specified mutation, biomarker, or disease‑specific finding required for the product (e.g., FLT3, ALK, FGFR, BRCA, IDH mutations; H3K27M; BRAF V600)

    Requirements and tests are product‑specific; prescriber specialty restrictions and prior therapy prerequisites may also apply.

    Reauthorization

    Reauthorization covered when ALL of the following are met:

    Reauthorization: For annual reauthorization submit documentation of symptomatic or clinical improvement (or maintenance of previously achieved benefit); provide updated objective tests as indicated (labs, imaging, Child‑Pugh, ECG, etc.)

    Specific reauthorization metrics vary by product (examples include reductions in exacerbation rate, improved lab values, decreased proteinuria, or histologic improvement).

    Time-limited use

    Covered when ALL of the following are met:

    Time‑limited use restrictions: Adhere to product‑specific maximum duration limits where specified due to safety (e.g., certain agents not approved beyond specified durations); documentation supporting limited duration use must be provided

    Example: some products have initial shorter authorizations (e.g., 6 months) then annual reauthorization; ORIAHNN use >2 years not approved for safety reasons.

    Inbrija (levodopa inhalation) authorization criteria

    Covered when ALL of the following are met:

    Inbrija (levodopa inhalation) initial: Patient is ≥18 years; prescriber is neurology; patient experiences 'off' episodes despite carbidopa/levodopa; tried and failed or intolerant to medications from at least two different classes to reduce off episodes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; no non‑selective MAOI use within 14 days; no chronic underlying lung disease (asthma, COPD)

    Annual reauthorization requires confirmation of symptomatic or clinical improvement or maintenance of previously achieved improvement.

    Pemazyre authorization criteria

    Covered when ALL of the following are met:

    Pemazyre initial authorization: Patient is ≥18 years; prescriber restricted to hematology/oncology; submit test confirming FGFR1 rearrangement or FGFR2 fusion/rearrangement as appropriate for indication; attest prior systemic treatment for the indication; no coadministration with moderate/strong CYP3A4 inducers

    Submit pregnancy status for females of childbearing potential; coverage duration 1 year.

    Prolastin-C authorization criteria

    Covered when ALL of the following are met:

    Prolastin‑C initial authorization: Diagnosis of alpha‑1 antitrypsin deficiency with pre‑treatment AAT level <11 mmol/L (80 mg/dL); confirmation of clinically evident emphysema attributable to congenital AAT deficiency by PFTs, imaging, or DLCO; prescriber restricted to pulmonology; ensure patient is not IgA‑deficient with anti‑IgA antibodiesAAT <11 mmol/L (80 mg/dL)

    Coverage duration 1 year; reauthorization requires confirmation of symptomatic or clinical improvement or maintenance of benefit; Part B vs Part D determination may depend on site-of‑care and administration details.

    Repatha authorization criteria

    Covered when ALL of the following are met:

    Repatha indications for initial authorization: For ASCVD or HeFH: LDL remains ≥70 mg/dL despite ≥8 weeks of high‑intensity statin therapy (or documented statin intolerance as specified); for HoFH similar LDL or intolerance criteria applyLDL ≥70 mg/dL despite ≥8 weeks high‑intensity statin

    Prescriber restricted to cardiology/endocrinology/lipid specialists; age ≥10 years for some indications; coverage duration 1 year.

    REVUFORJ Initial Therapy

    Covered when ALL of the following are met:

    REVUFORJ initial criteria: Diagnosis of covered use and submission of test confirming KMT2A translocation (excluding 11q23 partial tandem duplication or NPM1 mutation); submit baseline QTcF, serum potassium, serum magnesium, baseline WBC count, and pregnancy status for females of childbearing potential; prescriber restricted to hematology/oncology

    Coverage duration 1 year; exclusions include QTcF >450 msec at initiation, WBC >25 x10^9/L, uncorrected hypokalemia/hypomagnesemia, or coadministration with moderate/strong CYP3A4 inducers.

    REZDIFFRA Initial and Reauthorization

    Covered when ALL of the following are met:

    REZDIFFRA authorization: Diagnosis of covered use with confirmation of F2 or F3 fibrosis by biopsy, MR elastography, or vibration‑controlled elastography; submission of liver function testing or Child‑Pugh score; prescriber restricted to gastroenterology/hepatology; age ≥18F2 or F3 fibrosis

    Coverage duration 1 year; exclusion for decompensated cirrhosis or moderate/severe hepatic impairment; first reauthorization requires documentation of resolution or improvement/stabilization of fibrosis; annual reauthorizations require maintenance of clinical benefit.

    RIVFLOZA Initial and Reauthorization

    Covered when ALL of the following are met:

    RIVFLOZA authorization: Diagnosis of covered use with documentation of AGXT mutation by enzyme analysis or genetic testing; submission of 24‑hour urinary oxalate (Uox) ≥0.7 mmol (normalized for BSA in patients <18) and eGFR (must not be <30 mL/min/1.73 m2); attest patient has not had prior kidney or liver transplant and will not use concomitant lumasiran; prescriber restricted to nephrology or urology24‑hour Uox >=0.7 mmol; eGFR >=30 mL/min/1.73 m2

    Initial coverage 6 months then 1 year; first reauthorization requires clinically relevant response (reduced Uox or plasma oxalate); annual reauthorization requires maintenance of benefit.

    Antipsychotics Initial Therapy and Step Therapy

    Covered when ALL of the following are met:

    Antipsychotics initial authorization: Diagnosis of covered use and submission of prior therapy history; for schizophrenia or acute bipolar I manic/mixed episodes must have tried and failed or been intolerant to aripiprazole and at least one other generic second‑generation atypical antipsychotic; for Caplyta in bipolar depression must have tried and failed or been intolerant to at least two of cariprazine, lurasidone, olanzapine, or quetiapine

    Prescriber restricted to psychiatry; coverage duration 1 year; other indication‑specific step requirements apply.

    Simvastatin Prior Use Requirement

    Covered when ALL of the following are met:

    Simvastatin 80 mg prior use requirement: Diagnosis of covered use and documentation the patient has been taking simvastatin 80 mg daily for ≥30 days without adverse effects (or meets specified prerequisites) where applicable; age and other criteria per product labeling>= 30 days

    Not recommended as initial therapy; prior lower‑dose failure criteria apply; coverage duration 1 year.

    SIGNIFOR Initial and Reauthorization

    Covered when ALL of the following are met:

    SIGNIFOR authorization: Diagnosis of covered use with 24‑hour urine free cortisol demonstrating baseline >1.5× ULN (50 mcg or 145 nmol); attestation pituitary surgery not an option or not curative; submission of baseline LFTs and electrolytes (K, Mg); prescriber restricted to endocrinology>1.5× ULN 24‑hour UFC

    Exclusion for severe hepatic impairment (Child‑Pugh C) or uncorrected hypokalemia/hypomagnesemia; first reauthorization requires documentation of clinically relevant response; annual reauthorization requires maintenance of benefit; coverage 1 year.

    General authorization criteria

    Covered when ALL of the following are met:

    General product authorization: 1) Diagnosis of covered use documented; 2) Age meets product‑specific requirements; 3) Prescriber specialty restriction met where required; 4) Required laboratory or diagnostic confirmation submitted per product; 5) No exclusion criteria present for the product

    This template applies to multiple products; see product‑specific nodes for required tests, prior therapies, and exclusions.

    ATTR cardiomyopathy

    Covered when ALL of the following are met:

    ATTR diagnostic confirmation: Diagnosis of transthyretin amyloid cardiomyopathy (wild‑type or hereditary) confirmed by one of: cardiac biopsy with amyloid deposits; transthyretin precursor protein on immunohistochemistry; technetium‑99 SPECT demonstrating uptake; OR TTR genetic mutation plus cardiac involvement defined as interventricular septal wall thickening

    Prescriber restricted to cardiology; age ≥18; coverage duration 1 year; reauthorization requires documentation of symptomatic/clinical improvement or maintenance.

    Molecularly targeted oncology agents

    Covered when ALL of the following are met:

    Mutation‑directed oncology therapies: Submission of test confirming presence of the relevant mutation or biomarker required for the therapy (e.g., IDH1/2, FLT3, ALK, EGFR, MET exon 14 skipping, FGFR fusions) and documentation of prior therapies as specified per indication

    Prescriber restricted to oncology; exclusions and safety labs (e.g., QTcF, electrolytes) required per product; coverage typically 1 year.

    Tolvaptan (indication-specific criteria)

    Covered when ALL of the following are met:

    Tolvaptan for ADPKD: Diagnosis of rapidly progressing autosomal dominant polycystic kidney disease defined by Mayo Imaging Classification 1C–1E, historical eGFR decline ≥3 mL/min/1.73 m2 per year over 4 years, or PROPKD score >6; prescriber restricted to nephrology; submission of serum sodium and other labs

    Exclusions include significant liver impairment, inability to sense thirst, hypovolemia, urinary obstruction, anuria, coadministration with strong CYP3A modulators; coverage duration 1 year.

    Tolvaptan for hyponatremia: Evidence of clinically significant hyponatremia (serum sodium <125 mEq/L, or symptomatic serum sodium <135 mEq/L resistant to fluid restriction); initiate in a monitored setting where sodium can be closely followed30 days

    Treatment limited to 30 days to reduce risk of liver injury; exclusions similar to above; this formulation not approved for ADPKD.

    Parathyroid hormone analogs / osteoporosis

    Covered when ALL of the following are met:

    Parathyroid hormone analogs initial: Diagnosis with high fracture risk defined by specified fracture history and/or T‑score/FRAX thresholds; prior trial and inadequate response or intolerance to at least one bisphosphonate (therapeutic failure defined as fracture or BMD decrease while on bisphosphonate ≥3 months)

    Coverage duration typically 2 years; use beyond 2 years generally not recommended unless patient remains high risk and updated serum calcium provided for reauthorization.

    VEOZAH (vasomotor symptoms)

    Covered when ALL of the following are met:

    VEOZAH authorization: Patient must have tried and failed or been intolerant to at least two prior systemic hormone therapies or FDA‑approved/compendia‑supported non‑hormonal therapies for vasomotor symptoms from different classes; submit required labs (e.g., eGFR, LFTs) and pregnancy status as applicable

    Prescriber restrictions apply; coverage duration 1 year; annual reauthorization requires documentation of symptomatic improvement or maintenance.

    VERQUVO (heart failure)

    Covered when ALL of the following are met:

    VERQUVO authorization: Diagnosis of HFrEF with either hospitalization for HFrEF within prior 6 months or outpatient IV diuretic use within prior 3 months; left ventricular ejection fraction <45% submitted; prescriber restricted to cardiology; submit current heart failure regimen showing ACEi/ARB or sacubitril/valsartan, a beta‑blocker, and an MRA at maximally‑tolerated doses (or rationale for not using)LVEF <45%

    Exclusions include pregnancy and concomitant use of another sGC stimulator or a PDE‑5 inhibitor; coverage duration 1 year; annual reauthorization requires confirmation of clinical benefit or maintenance.

    General product authorization logic

    Covered when ALL of the following are met:

    General product pattern: 1) Diagnosis of covered use documented; 2) Required labs/tests submitted (e.g., eGFR, LFTs); 3) Age and prescriber restrictions satisfied; 4) Prior therapy trials as specified; 5) No product‑specific exclusion criteria present

    Pattern applies across many products; see per‑product entries for specificity.

    Wegovy (MASH / MACE) criteria

    Covered when ALL of the following are met:

    Wegovy for MACE risk reduction: Documentation of established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD as defined) and BMI ≥25 kg/m2; attest patient is not using semaglutide for diabetes; attestation regarding current cardiovascular risk regimenBMI >=25 kg/m2

    Initial authorization 32 weeks then 1 year; prescriber and prior therapy documentation required; not approved for weight management under Medicare Part D.

    Wegovy for MASH: Confirmation of F2 or F3 fibrosis by biopsy or elastography and submission of LFTs/Child‑Pugh; first reauthorization requires resolution or improvement of fibrosis; annual reauthorization requires maintenance of benefitF2 or F3 fibrosis

    Initial 32 weeks then 1 year.

    Voydeya coverage criteria

    Covered when ALL of the following are met:

    Voydeya initial: Patient has clinically significant extravascular hemolysis defined as hemoglobin ≤9.5 g/dL and absolute reticulocyte count ≥120 x10^9/L after stable use of a complement C5 inhibitor; patient is receiving eculizumab or ravulizumab; prescriber restricted to hematologyHb <=9.5 g/dL; reticulocytes >=120 x10^9/L

    Standalone therapy excluded; initial authorization 6 months then 1 year; reauthorization requires documentation of clinical benefit or maintenance.

    Xifaxan criteria

    Covered when ALL of the following are met:

    Xifaxan indications: For hepatic encephalopathy (HE): trial and inadequate response or intolerance to lactulose required; for IBS‑D: trial and inadequate response to ≥2 classes (antidiarrheals, antispasmodics, TCAs); for SIBO: positive carbohydrate breath test and failure of ≥2 other agents with efficacy evidenceIBS‑D: max 3 lifetime 14‑day courses; SIBO: max 2 14‑day courses per 365 days

    Coverage durations differ: HE 1 year; IBS‑D and SIBO typically 14 days per course.

    PAH criteria

    Covered when ALL of the following are met:

    PAH product criteria (example): Diagnosis confirmed by right heart catheterization with mPAP >20 mm Hg, PCWP ≤15 mm Hg, and PVR >2 Woods units; WHO Group 1 with NYHA functional class II–IV; submission of baseline platelet count and prior/ongoing medications including at minimum a nitric oxide pathway mediator and an endothelin receptor antagonistmPAP >20 mm Hg; PCWP <=15 mm Hg; PVR >2 Woods units

    Initial authorization often 6 months then 1 year; prescriber restricted to cardiology/pulmonology; exclusions include pregnancy and specified drug interactions.

    Omalizumab — initial and reauthorization criteria (examples)

    Covered when ALL of the following are met:

    Omalizumab initial (asthma/CRSwNP/CSU examples): Indication‑specific prerequisites: asthma — patient on GINA‑recommended maximally‑tolerated ICS+LABA+LAMA and provider attests background therapy will continue; CRSwNP — intranasal corticosteroid trial ≥2 months (or contraindication) and attestation it will continue; CSU — trial of ≥30 days oral antihistamine with persistent symptoms; submit required objective tests per indication2 months (CRSwNP intranasal steroid); 30 days (CSU oral antihistamine)

    Reauthorization requires documentation of clinical benefit (reduction in exacerbations, symptom scores, nasal polyp score, itch/hive counts) or maintenance of prior benefit; prescriber restrictions and age limits per product.

    Product-specific initial authorization and reauthorization criteria

    Covered when ALL of the following are met (selected product examples):

    XOSPATA: Diagnosis of covered use with test confirming FLT3 mutation; baseline serum potassium and magnesium submitted; prescriber restricted to hematology/oncology; exclusion for uncorrected hypokalemia/hypomagnesemia and coadministration with dual strong CYP3A/P‑gp inducers

    Coverage duration 1 year; age ≥18.

    ZILBRYSQ: Diagnosis confirmed with abnormal neuromuscular transmission tests or improvement with acetylcholinesterase inhibitors and positive AChR‑Ab; submission of MGFA classification (class II–IV) and baseline MG‑ADL ≥6; attestation patient will not concurrently use rituximab or eculizumab and is vaccinated against N. meningitidis A,B,C,W,Y; initial trials require failures in at least one drug in two of three classes (acetylcholinesterase inhibitors, corticosteroids, non‑steroidal immunosuppressives)MG‑ADL >=6; MGFA II–IV

    Initial coverage 6 months then 1 year; reauthorization requires clinical improvement and maintenance.

    XPOVIO and other oncology agents: Diagnosis and pregnancy status submitted; prior systemic therapy failures documented as specified by indication; prescriber restricted to hematology/oncology; coverage duration typically 1 year

    Product‑specific exclusions such as QT prolongation, hepatic impairment, or strong CYP3A interactions apply.

    This policy requires prior authorization for pulmonary hypertension agents and specifies several exclusionary safety conditions. Coverage is contingent on diagnostic confirmation by right heart catheterization with submission of WHO group classification and hemodynamic data including mean pulmonary arterial pressure >20 mm Hg and pulmonary arterial wedge pressure ≤15 mm Hg; for PAH (WHO Group 1) PVR >2 Woods units is required and for CTEPH (WHO Group 4) PVR >3 Woods units plus imaging evidence of chronic pulmonary embolism and attestation of inoperable or persistent/recurrent disease. Exclusions that may trigger denial include pregnancy, severe hepatic impairment (Child‑Pugh class C), creatinine clearance <15 mL/min or dialysis, and contraindicated co‑medications such as nitrates/nitric oxide donors or phosphodiesterase inhibitors. Prescriber specialty is restricted (cardiology or pulmonology) and typical coverage duration is 1 year. Initial PAH authorization additionally requires prior inadequate response, intolerance, or contraindication to both a PDE5 inhibitor (sildenafil or tadalafil) and an ERA (ambrisentan or bosentan).

    AQNEURSA (for Niemann‑Pick disease type C) is excluded when patients do not have neurologic manifestations consistent with the diagnosis or when pregnancy is present. Prior authorization requires documentation of the neurologic signs or symptoms attributable to Niemann‑Pick type C and submission of pregnancy status for females of childbearing potential. Reauthorization requires confirmation of symptomatic or clinical improvement (or maintenance of previously achieved improvement). Coverage is generally limited to patients aged 18 years or older where specified and prescriber access is restricted to neurology.

    Chenodal is excluded for patients who are pregnant or who have known hepatocyte dysfunction, significant bile duct abnormalities (including intrahepatic cholestasis, primary biliary cirrhosis, or sclerosing cholangitis), radiopaque gallstones, or a nonvisualizing gallbladder after two consecutive dye doses; safety beyond 24 months has not been established and extended use will not be authorized. Prior authorization requires documentation of the diagnosis and submission of liver function testing; prescriber specialty is limited to gastroenterology or hepatology. Coverage duration in the policy is limited to 24 months for this agent.

    Cerdelga (eliglustat) coverage excludes patients who are ultrarapid CYP2D6 metabolizers and those with pre‑existing cardiac disease or long QT syndrome, and it is not recommended in moderate or severe hepatic impairment. Prior authorization requires submission of CYP2D6 genotype/metabolizer status and liver function testing or a Child‑Pugh score. These safety exclusions and required baseline tests must be reviewed before approval; typical coverage duration when authorized is 1 year.

    Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    Prior authorization required

    Prior authorization (PA) is required for drugs listed with “PA” on the Medicare Advantage Part D formulary; approval must be obtained before filling prescriptions to be eligible for coverage. Failure to obtain prior authorization may result in the drug not being covered.

    • Obtain approval prior to dispensing to be eligible for coverage.
    • Drugs appear with ‘PA’ in the Requirements/Limits column on the formulary.
    Step Therapy

    Therapy trial required for some agents

    Document prior trial and failure or intolerance to required therapies when specified (example: AUSTEDO initial authorization for Huntington chorea requires trial/failure or intolerance to tetrabenazine).

    • Include dates, doses, and reason for discontinuation (failure or intolerance).
    • If prerequisite therapy cannot be used, document contraindication or intolerance.
    Prior Authorization

    Cholestasis drug PA — initial 6 months then annual

    For cholestasis-related products, initial authorization is limited to 6 months (then annual reauthorization) and requires the prescriber be gastroenterology/hepatology; submit molecular genetic testing and documentation of cholestasis and prior trials of at least two listed agents.

    • Submit molecular genetic test confirming diagnosis and evidence of cholestasis (e.g., total serum bile acid > age‑adjusted ULN, conjugated bilirubin, GGT elevation, fat‑soluble vitamin deficiency, or intractable pruritus).
    • Document failure/intolerance to at least two of: cholestyramine, naltrexone, rifampin, ursodiol; first reauthorization requires LFTs and attestation of symptomatic improvement.
    Prior Authorization

    Caplacizumab PA and recurrence limit

    Caplacizumab (CABLIVI) requires prior authorization; patient must be ≥12 years, prescriber restricted to cardiology/hematology/immunology, and coverage duration is 3 months. If not first use, submit prior aTTP recurrences; do not authorize if >2 recurrences while on therapy.

    • Confirm drug will be given with plasma exchange and immunosuppressive therapy.
    • If request is for subsequent use, submit number of prior aTTP recurrences while on caplacizumab; coverage denied if >2 recurrences.
    Prior Authorization

    CAMZYOS PA — cardiology prescriber and prior trials required

    CAMZYOS prior authorization is required; restricted to cardiology prescribers, age ≥18, initial coverage 1 year, and initial authorization requires prior trial and failure or intolerance to both a beta‑blocker and a non‑DHP calcium channel blocker.

    • Submit attestation of NYHA class II–III exertional symptoms, LVOT gradient ≥50 mm Hg (rest/Valsalva/exercise), LV wall thickness ≥15 mm (or ≥13 mm if familial), and current LVEF.
    • Annual reauthorization requires confirmation of symptomatic improvement or maintenance.
    Prior Authorization

    CFTR modulators — mutation confirmation and pulmonology prescriber

    CFTR modulators require submission of CFTR mutation testing confirming the specific mutation(s) responsive per drug labeling and are restricted to pulmonology prescribers; coverage duration is 1 year.

    • Attach CFTR mutation test results showing mutation(s) responsive to the requested drug (per prescribing information or in vitro data).
    • Prescriber must be pulmonology; annual reauthorization requires documentation per product.
    Prior Authorization

    Migraine biologics — baseline/headache and prior triptan/biologic trials

    CGRP monoclonal antibodies for migraine prevention require documentation of baseline headache days and prior acute therapy trials; Emgality prevention specifically requires prior failure or intolerance to Aimovig and initial prevention authorization is 3 months then 1 year.

    • For prevention: document baseline headache days/month (<15 for episodic prevention) and submit on‑treatment headache days at first reauthorization demonstrating improvement.
    • For acute treatment: document trial/failure or contraindication to one triptan.
    Prior Authorization

    Antiemetic products PA (age ≥18)

    Prior authorization is required for listed antiemetic products for patients aged ≥18; coverage duration is 1 year. If used as a full replacement for IV antiemetic therapy within 48 hours of cancer treatment, prescriber must indicate Part B on the prescription.

    • For cancer‑related use, submit prior/current antiemetic therapies and prescriber attestation for Part B coverage when replacing IV therapy within 48 hours.
    • Typical PA duration: 1 year for outpatient use.
    Prior Authorization

    Dupilumab PA — initial 6 months then annual; submit diagnostics/prior therapy

    Dupilumab requires prior authorization with initial coverage typically 6 months then 1 year; submit indication‑specific diagnostic confirmation and prior/concomitant therapy per indication (e.g., topical steroid trial for AD; GINA‑recommended maximal inhaled regimen for asthma; intranasal corticosteroid for CRSwNP; biopsy for EoE).

    • For each indication, attach the required objective tests (e.g., FEV1 and blood eosinophils for asthma; endoscopy/biopsy showing ≥15 eos/HPF for EoE).
    • Provider must attest continuation of background therapies where required; first reauthorization requires documentation of clinical benefit or maintenance.
    Prior Authorization

    Eltrombopag PA — diagnosis, platelet thresholds, prior therapies

    Eltrombopag prior authorization requires documentation of diagnosis, indication‑specific platelet count thresholds, submission of prior therapies tried and failed (for ITP), and updated platelet counts for reauthorization; durations vary by indication.

    • For ITP initial: platelet count <30 x10^9/L or <50 x10^9/L with increased bleeding risk and trials of ≥2 ITP therapies (or splenectomy status).
    • For reauthorization, submit platelet response (≥50 x10^9/L after ≥4 weeks on max tolerated dose) and maintenance documentation.
    Prior Authorization

    ENSACOVE PA — ALK+ confirmation and no prior ALK inhibitor

    ENSACOVE (ALK inhibitor) prior authorization requires documentation of an ALK‑positive tumor test, attestation of no prior ALK‑inhibitor use, pregnancy status, prescriber restricted to oncology, and coverage duration 1 year; prior ALK‑inhibitor use is exclusionary.

    • Submit tumor testing confirming ALK positivity and attest patient has not previously received an ALK inhibitor.
    • Do not approve if prior ALK‑inhibitor use is documented; include pregnancy status for females of childbearing potential.
    Documentation Required

    EOHILIA PA — biopsy confirmation, prior PPI trial, prescriber limits

    EOHILIA prior authorization requires upper endoscopy with biopsy showing ≥15 eos/HPF (or 60 eos/mm2), documentation of signs/symptoms, prior 8‑week PPI trial, prescriber specialty restrictions, and allows a single 12‑week course every 365 days (coverage duration 12 weeks).

    • Attach endoscopy pathology showing eosinophilic criteria and documentation of prior PPI trial and symptoms.
    • Prescriber must be allergy, gastroenterology, immunology, or ENT; maximum one 12‑week course per 365 days.
    Prior Authorization

    EPIDIOLEX PA — neurology prescriber required

    EPIDIOLEX prior authorization requires prescriber be neurology and coverage duration is 1 year; PA is required for FDA‑approved indications.

    • Submit diagnosis of covered indication and neurology prescriber information.
    • Annual reauthorization requires documentation per product.
    Denial Risk

    FRUZAQLA PA — QTc/electrolyte/hepatic exclusions and baseline labs

    FRUZAQLA PA requires baseline QTc and electrolytes and excludes patients with QTc >450 msec, significant electrolyte abnormalities, severe hepatic impairment, coadministration with strong CYP3A4 inhibitors, or recent MAOI use; submit baseline QTc, potassium, magnesium, and LFTs.

    • Do not initiate if QTc >450 msec or congenital long QT syndrome; correct hypokalemia/hypomagnesemia prior to initiation.
    • Avoid coadministration with strong CYP3A4 inhibitors and MAOI within 14 days.
    Prior Authorization

    FABHALTA PA — diagnostic confirmation and prior therapy required

    FABHALTA prior authorization requires diagnostic confirmation (e.g., flow cytometry for PNH), relevant labs, prescriber specialty restrictions to hematology/nephrology, and prior therapy failure for indicated uses; coverage duration 1 year.

    • For PNH: submit flow cytometry confirming PNH clones and evidence of inadequate response to eculizumab or ravulizumab.
    • For IgAN: submit UPCR ≥1.5 g/g and documentation of failure/intolerance to maximally‑tolerated ACEi/ARB and atrasentan or sparsentan.
    Prior Authorization

    FILSPARI PA — biopsy confirmation, UPCR thresholds, prior ACEi/ARB

    FILSPARI prior authorization requires biopsy‑confirmed primary IgA nephropathy, specified urine protein thresholds, eGFR and liver testing, prescriber restriction to immunology/nephrology, and prior maximally tolerated ACE inhibitor/ARB use; annual reauthorization requires clinically relevant response.

    • Submit kidney biopsy confirming IgAN and either 24‑hour urine protein ≥0.5 g/day or UPCR ≥0.8 g/g, with eGFR and liver tests.
    • Document trial and inadequate response or intolerance to a maximally‑tolerated ACE inhibitor or ARB prior to initiation.
    Prior Authorization

    Oncology‑related products — prescriber, labs, exclusions, prior therapy

    Oncology and other specialty agents frequently require prior authorization with prescriber specialty restrictions to oncology/hematology, baseline labs (e.g., QTc, K/Mg, LFTs), exclusions for interacting drugs or comorbidities, and documentation of prior systemic therapies when specified.

    • Submit tumor/mutation testing as required (e.g., FGFR, KMT2A, FLT3) and baseline safety labs (QTcF, potassium, magnesium, LFTs) when requested.
    • Confirm prescriber specialty matches policy requirement (hematology/oncology) to avoid denial.
    Prior Authorization

    GLP‑1 agents PA — diabetes diagnosis required; weight‑loss use excluded

    GLP‑1 receptor agonists and related diabetes agents require documentation of type 2 diabetes diagnosis (medical record, ICD‑10, or lab results); prior authorization is required with coverage duration 1 year; off‑label use for weight management is excluded under Medicare Part D.

    • Attach evidence of type 2 diabetes (A1c, fasting glucose, OGTT, or medical record).
    • Do not request GLP‑1 products for weight management under Medicare Part D—this use will be denied.
    Documentation Required

    Norditropin PA — growth failure documentation and labs

    Norditropin prior authorization requires documentation of growth failure and relevant labs (IGF‑1, height/weight, creatinine clearance or serum creatinine, fasting glucose, bone age if applicable); prescriber restricted to endocrinology/nephrology and annual reauthorization requires updated monitoring.

    • Submit IGF‑1 levels, growth measurements, creatinine clearance (or serum creatinine), fasting glucose, and bone age when applicable.
    • Prescriber must be endocrinology or nephrology; include updated labs on reauthorization.
    Prior Authorization

    HAE agents PA — prophylaxis documentation, prescriber limits

    HAE prophylaxis agents require prior authorization, coverage duration 1 year, and prescriber restriction to allergy/dermatology/hematology/immunology; requests for acute HAE attack therapy or prophylaxis where excluded must be avoided.

    • Submit objective or subjective documentation that prophylactic therapy is medically necessary (attack frequency, disease activity, QoL).
    • Ensure the request is for prophylaxis in an approved product; some HAE products exclude prophylaxis or acute therapy—verify product‑specific rules.
    Prior Authorization

    Antifungal PA — baseline labs and 6‑month initial coverage

    Certain antifungal agents (example: KISQALI entries) require prior authorization and baseline labs (ALT, AST, total bilirubin, alkaline phosphatase, PT/INR); coverage duration is 6 months for these entries and infections of skin or nails or fungal meningitis are excluded.

    • Submit culture‑proven diagnosis for systemic mycoses listed and baseline LFTs and coagulation studies.
    • Do not request these antifungal agents for fungal meningitis or cutaneous/nail infections—these are excluded.
    Prior Authorization

    KOMZIFTI PA — tumor testing and safety labs required

    KOMZIFTI prior authorization requires oncology prescriber, age ≥18, submission of genetic tumor testing confirming HR‑positive, HER2‑negative primary tumor, QTcF and electrolyte labs within prior 6 months, pregnancy status, and coverage duration 1 year.

    • Attach genetic tumor testing confirming HR+/HER2‑ status and recent QTcF, serum potassium and magnesium.
    • Attest concomitant use of an aromatase inhibitor or fulvestrant as indicated.
    Note
    Prior Authorization

    PA requirement overview — submit diagnosis, labs, and prescriber specialty

    Prior authorization is required for the listed specialty products generally; providers must meet exclusion criteria, submit required medical information (diagnosis, labs, mutation testing, pregnancy status), and adhere to prescriber/age restrictions to obtain approval.

    • Failure to submit required baseline labs, mutation tests, or pregnancy status may trigger denial.
    • Confirm patient meets age and prescriber specialty requirements before submission.
    Billing Rule

    Limited‑duration PA — monitored initiation (e.g., tolvaptan 30 days)

    Some agents have limited‑duration prior authorizations and must be initiated in monitored settings (example: tolvaptan for hyponatremia is limited to 30 days and must be started where serum sodium can be closely monitored).

    • For tolvaptan hyponatremia formulation: submit evidence of clinically significant hyponatremia (serum Na <125 mEq/L or symptomatic <135 mEq/L resistant to fluid restriction).
    • Document setting of initiation (hospital/outpatient monitored setting) and plan for sodium monitoring.
    Note
    Note
    Note
    Note
    Note
    Note
    Step Therapy

    Prior therapy requirement — document trials/failures or intolerance

    Prior authorization typically requires documentation of prior therapies tried and failed (or intolerance) before approval (examples include BYLVAY, BYLVAY‑class cholestasis agents, many biologics, and oncology agents).

    • Provide dates, doses, and reasons for discontinuation of prior therapies; where product requires ≥2 prior agents, list each trial and outcome.
    • If a required prior therapy was not used, document contraindication or intolerance.
    Prior Authorization

    Rifaximin prerequisite — lactulose trial required for HE

    Rifaximin (XIFAXAN) authorization for hepatic encephalopathy requires trial and inadequate response or intolerance to lactulose before approval; for IBS‑D and SIBO, document prior therapy courses and testing as specified.

    • For HE: document lactulose trial and inadequate response/intolerance.
    • For IBS‑D: document number of prior 14‑day rifaximin courses in lifetime; for SIBO: positive carbohydrate breath test and prior courses in previous 365 days.
    Documentation Required

    Document prerequisite/background therapy and attestation

    Providers must document prerequisite/background therapies and attest that guideline‑recommended background therapies will be continued where specified (examples: asthma biologics require maximally‑tolerated ICS+LABA+LAMA; HFrEF/PAH products require use of guideline background therapies).

    • Include attestation that background therapies will continue after biologic initiation when required.
    • For HFrEF or PAH agents, document current guideline background regimen and doses.
    Note

    Index entries — consult product‑specific sections for PA rules

    Index entries in this extract list drug names and formulations but do not state specific prior authorization requirements; individual drug sections elsewhere in the policy contain the requirements and must be referenced for PA submission.

    • When using the index, navigate to the product‑specific section for PA rules, required documentation, and exclusions.
    • Do not rely on index alone for authorization — submit product section evidence.
    Step Therapy

    Preferred‑agent step requirement for biologics

    For many biologic/immunomodulator agents, initial authorization requires trials of at least two preferred agents where possible prior to starting the requested biologic (document each preferred‑agent trial and reason for failure/intolerance).

    • List preferred agents tried, durations, outcomes, and reasons for discontinuation.
    • If preferred agents cannot be used, provide documentation of contraindication or intolerance.

    Codes, Thresholds, and Key Clinical Values

    Listed diabetes/GLP-1 productsmixed
    N/AProduct listings for MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY and related formulations (no billing codes provided in this excerpt)
    Valtoco dosesmixed
    10 mgVALTOCO 10 MG DOSE
    15 mgVALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 2 X 7.5 MG/0.1ML
    20 mgVALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 2 X 10 MG/0.1ML
    5 mgVALTOCO 5 MG DOSE
    RepathaNDC
    REPATHAREPATHA products (including Pushtronex, SureClick)
    Product descriptions (no billing codes provided)mixed
    NDC/HCPCS not listedSpecific product strengths and formulations listed (e.g., teriparatide pen 560 mcg/2.24 mL) but no billing codes provided in this section.
    No explicit CPT/HCPCS/NDC codes in this partmixed
    No codes listed
    Listed products and formulations (no billing codes provided)mixed
    N/AThis window contains no explicit CPT/HCPCS/ICD-10/NDC codes; product names and formulations are listed instead.
    Index entries (no billing codes in excerpt)mixed
    No codes listed
    inv-100: Mean pulmonary arterial pressure — hemodynamic threshold for PAH
    Mean pulmonary arterial pressure (mPAP)> 20 mm Hg
    ContextRequired at rest as part of right heart catheterization confirmation for PAH
    Applies toWHO Group 1 (PAH) and referenced in combined PAH hemodynamic criteria
    inv-101: Pulmonary arterial wedge pressure — hemodynamic threshold
    Pulmonary arterial wedge pressure (PAWP/PCWP)≤ 15 mm Hg
    ContextMeasured during right heart catheterization to distinguish pre- vs post-capillary PH
    Applies toPAH diagnostic hemodynamic criteria (WHO Group 1)
    inv-102: PVR for PAH — pulmonary vascular resistance threshold
    Pulmonary vascular resistance (PVR) for PAH> 2 Woods units
    Measured byCalculated from right heart catheterization; required for WHO Group 1 PAH documentation
    Reference notePAH criteria often combined with mPAP >20 mm Hg and PCWP ≤15 mm Hg
    inv-103: PVR for CTEPH — pulmonary vascular resistance threshold for CTEPH
    Pulmonary vascular resistance (PVR) for CTEPH> 3 Woods units
    ContextRequired for WHO Group 4 (CTEPH) in addition to imaging evidence of chronic PE and inoperable/persistent disease
    Measured byRight heart catheterization
    inv-104: BYLVAY initial therapy failures required — numeric prior-failure requirement
    Required prior failures for BYLVAY initial authorization>= 2 listed agents (e.g., cholestyramine, naltrexone, rifampin, ursodiol)
    Prescriber restrictionGastroenterology or hepatology
    Initial coverage duration6 months then 1 year
    inv-105: LV outflow tract gradient — CAMZYOS threshold
    LV outflow tract (LVOT) gradient threshold≥ 50 mm Hg (rest, Valsalva, or after exercise)
    Additional cardiac criteriaLV wall thickness ≥15 mm (≥13 mm if familial); attest NYHA II/III symptoms and submit current LVEF
    Prescriber restrictionCardiology
    inv-106: Asthma blood eosinophils — eosinophil threshold for asthma indications
    Asthma blood eosinophil threshold≥150 cells/mcL obtained within 6 weeks of therapy initiation (or daily OCS dependence criteria)
    ContextRequired as part of diagnostic/eligibility testing for biologic agents (e.g., dupilumab, mepolizumab)
    Documentation timingSample must be obtained within 6 weeks of therapy initiation per criteria
    inv-107: COPD blood eosinophils — eosinophil threshold for COPD indications
    COPD blood eosinophil threshold≥300 cells/mcL obtained within 6 weeks of therapy initiation
    ContextUsed to support indication for certain biologics in COPD when symptomatic criteria met
    Documentation timingBlood eosinophil count within 6 weeks of therapy initiation
    inv-108: ITP platelet response for reauthorization — platelet threshold for response
    ITP platelet response for reauthorization≥50 x 10^9/L after ≥4 weeks on maximum tolerated dose
    Reauthorization requirementSubmit updated platelet count demonstrating improvement and maintenance
    Initial ITP threshold contextInitial ITP authorization often requires platelet <30 x10^9/L or <50 x10^9/L with bleeding
    inv-109: Blood eosinophil count for asthma/COPD — combined eosinophil criteria
    Combined blood eosinophil criteria (asthma/COPD)Asthma: ≥150 cells/mcL within 6 weeks or daily oral corticosteroid dependence; COPD: ≥300 cells/mcL within 6 weeks
    PurposeUsed to determine eligibility for biologic therapies across indications
    DocumentationSubmit blood eosinophil count and relevant pulmonary function or clinical data per indication
    inv-110: Platelet count thresholds (eltrombopag) — thresholds by indication
    Eltrombopag platelet thresholds by indicationITP: <30 x10^9/L (or <50 x10^9/L with increased bleeding risk); chronic hepatitis C: <75 x10^9/L; aplastic anemia: <30 x10^9/L
    ReauthorizationUpdated platelet counts demonstrating improvement required for continued use
    Prescriber restrictionHematology; provide prior therapy documentation for ITP
    inv-111: Eosinophils for EoE — diagnostic biopsy thresholds
    EoE diagnostic biopsy threshold>=15 eosinophils per high-power field (HPF) or 60 eos/mm2
    Additional requirementsDocument signs/symptoms and prior 8-week PPI trial to rule out reflux-related eosinophilia
    Age limitApproved for patients ≥11 years in criteria
    inv-112: Proteinuria thresholds — FABHALTA and FILSPARI proteinuria thresholds
    Proteinuria threshold — FABHALTA (IgAN)UPCR ≥1.5 g/g
    Proteinuria threshold — FILSPARI24-hour protein ≥0.5 g/day OR UPCR ≥0.8 g/g
    ContextRequired for initial authorization and reauthorization monitoring; submit eGFR and liver testing as specified
    inv-113: QTc exclusion — QTc threshold used to exclude initiation
    QTc exclusion threshold>450 msec at treatment initiation
    ContextExclusionary criterion for drugs with QT risk (e.g., FRUZAQLA, many oncology agents); baseline ECG required
    Additional exclusionsCongenital long QT syndrome, uncorrected hypokalemia/hypomagnesemia also exclusionary
    inv-114: Blood eosinophil count — variable thresholds depending on indication
    Variable blood eosinophil thresholds by indication≥150 cells/mcL within 6 weeks or ≥300 cells/mcL within 12 months (varies by product/indication)
    UseApplied across multiple biologics to establish eosinophilic phenotype for eligibility
    DocumentationSubmit timing of eosinophil measurement relative to therapy initiation as specified
    inv-115: Initial coverage duration for specified product — initially 6 months then 1 year
    Initial coverage duration (example)Initially 6 months, then 1 year
    ContextUsed for select products requiring an initial shorter trial period prior to standard annual reauthorization (e.g., some cholestasis-related or genetic disorder therapies)
    ReauthorizationAnnual reauthorization thereafter with documentation of clinical benefit required
    inv-116: 24-hour urine free cortisol (UFC) — biochemical threshold for certain endocrine agents
    24‑hour urine free cortisol (UFC) threshold>1.5 times upper limit of normal (50 micrograms or 145 nmol)
    ContextRequired baseline biochemical confirmation for agents treating Cushing's syndrome (e.g., Recorlev, SIGNIFOR)
    Required testsECG including QTcF and liver function tests often required alongside UFC
    inv-117: Hemoglobin for Retacrit — hemoglobin threshold for initiation
    Hemoglobin threshold for Retacrit initiation< 10 g/dL (for non-surgery indications at initial submission)
    ContextRequired documentation at initial PA for erythropoiesis-stimulating agent Retacrit
    ReauthorizationFollow-up labs and clinical response required per product-specific rules
    inv-118: 24-hour urinary oxalate (Uox) — RIVFLOZA diagnostic threshold
    24‑hour urinary oxalate (Uox) threshold for RIVFLOZA>= 0.7 mmol (normalize to BSA if patient <18 years)
    ContextRequired with documentation of AGXT mutation by enzyme analysis or genetic testing; eGFR must also be provided
    Initial coverage durationInitially 6 months then 1 year; first reauthorization requires reduction in Uox or plasma oxalate
    inv-119: Simvastatin 80 mg duration — required prior use duration
    Required duration of simvastatin 80 mg prior use>= 30 days
    ContextPA for simvastatin 80 mg or ezetimibe-simvastatin requires documentation patient has been taking simvastatin 80 mg daily for ≥30 days without adverse effects
    Age noteApplies to patients age ≥10 for certain indications per policy
    inv-120: SIGNIFOR baseline 24-hour UFC — SIGNIFOR baseline biochemical threshold
    SIGNIFOR baseline 24‑hour UFC threshold>1.5 times ULN (50 micrograms or 145 nmol)
    ContextRequired baseline biochemical confirmation for SIGNIFOR; baseline LFTs and electrolytes also required
    ReauthorizationDocument clinically relevant response (UFC reduction) for first reauthorization
    inv-121: Hyponatremia definition for tolvaptan (hyponatremia) — numeric definitions for serum sodium
    Hyponatremia definition for tolvaptan (hyponatremia formulation)Serum sodium <125 mEq/L OR symptomatic serum sodium <135 mEq/L resistant to fluid restriction
    Treatment durationLimited to 30 days; initiation in monitored setting where serum sodium can be closely monitored
    ExclusionsUnderlying liver disease, inability to sense thirst, coadministration with strong CYP3A modifiers or desmopressin
    inv-122: LVEF threshold for Verquvo — left ventricular ejection fraction requirement
    LVEF threshold for Verquvo (HFrEF)Left ventricular ejection fraction <45%
    ContextRequired along with recent hospitalization for HFrEF or outpatient IV diuretic use; prescriber restricted to cardiology
    ExclusionsConcomitant use of another sGC stimulator or PDE‑5 inhibitor and pregnancy
    inv-123: BMI — body mass index threshold referenced (e.g., Wegovy)
    BMI threshold referenced (e.g., Wegovy)>= 25 kg/m2
    ContextUsed in specific Wegovy criteria for MACE risk reduction; requires documentation of established cardiovascular disease
    Initial durationInitial 32 weeks then 1 year for Wegovy indications referenced
    inv-124: Urine protein (IgAN) — UPCR/24-hour protein thresholds
    Urine protein thresholds for IgAN24-hour urine protein >= 0.5 g/day OR UPCR >= 0.8 g/g (FILSPARI) — FABHALTA IgAN: UPCR >=1.5 g/g
    ContextRequired biopsy confirmation for IgAN (FILSPARI) and prior ACEi/ARB therapy; submit eGFR and liver tests
    ReauthorizationDocument clinically relevant response (stabilization or improvement in UPCR) for annual reauthorization
    inv-125: PAH hemodynamics — combined hemodynamic thresholds for PAH
    Combined PAH hemodynamic thresholdsmPAP >20 mm Hg; PCWP ≤15 mm Hg; PVR >2 Woods units
    ContextRequired from right heart catheterization for PAH (WHO Group 1) confirmation; WHO Group 4 (CTEPH) uses PVR >3 Woods units plus imaging evidence
    Related documentationSubmit WHO group classification, creatinine clearance, pregnancy status, and current/prior therapies
    inv-126: Pre-treatment serum IgE for XOLAIR — IgE threshold for certain indications
    Pre‑treatment serum IgE for XOLAIR>= 30 IU/mL (in patients ≥12 years for certain indications)
    ContextRequired for specific omalizumab/Xolair indications per labeling and policy
    Age noteApplies to patients ≥12 years where specified
    inv-127: Topical therapy trial duration for CRSwNP and intranasal corticosteroid — trial duration threshold
    Topical intranasal corticosteroid trial duration for CRSwNPAt least 2 months
    PurposeRequired prior therapy before initial biologic authorization for CRSwNP (e.g., dupilumab, omalizumab)
    DocumentationProvider must attest intranasal corticosteroid will be continued after starting biologic or document contraindication
    inv-128: Oral antihistamine trial duration for CSU — trial duration threshold
    Oral antihistamine trial duration for CSUAt least 30 days
    ContextRequired prior trial before initial biologic authorization for chronic spontaneous urticaria (CSU)
    ReauthorizationDocumentation of clinical benefit (reduction in itch or hive count) required for continuation

    Initial Authorization / Start-of-Therapy Rules

    Reauthorization / Ongoing Use Requirements

    Step Therapy & Prior-Use Requirements

    Step therapy ruleRequirement
    Preferred-agent step requirement
    For initial authorization of many biologic/immunomodulator agents the patient must have tried and failed to have an adequate response to or been intolerant to at least two preferred agents (examples: adalimumab biosimilar, Cosentyx, Enbrel, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/Xeljanz XR), where possible.
    Step therapy ruleRequirement
    AUSTEDO prior trial requirement
    For initial authorization of AUSTEDO for chorea associated with Huntington disease, the patient must have tried and failed to have an adequate response to or had an intolerance/contraindication to tetrabenazine.
    Step therapy ruleRequirement
    Cholestasis step therapy
    For initial authorization the patient must have tried and failed to have an adequate response to or been intolerant of at least two agents among cholestyramine, naltrexone, rifampin, or ursodiol; documentation of cholestasis and molecular genetic testing is required.
    Step therapy ruleRequirement
    CGRP biologic prior trial
    For initiation of Emgality for migraine prevention the patient must have tried and failed to have an adequate response to or been intolerant of Aimovig prior to initial authorization.
    Step therapy ruleRequirement
    Examples of step therapy or prior trials required
    Step therapy or prior trial of listed agents is required before approval in many product‑specific indications (examples include: moderate‑strength topical corticosteroid trial ≥4 weeks for dupilumab in AD; failure of maximally‑tolerated ACE inhibitor/ARB ± additional agents prior to FABHALTA or FILSPARI; prior systemic therapy failures as specified for oncology agents).
    Step therapy ruleRequirement
    Endocrine/oncology step requirement (PIQRAY example)
    For PIQRAY initial authorization the patient must have tried and failed to have an adequate response to an endocrine‑based regimen; documentation of prior endocrine therapy and rationale is required.
    Step therapy ruleRequirement
    Prior lines / prior‑therapy line requirements
    Some agents require failure of specified prior lines of therapy before initial authorization (examples: mantle cell lymphoma or CLL/SLL agents require failure of two prior lines including a BTK inhibitor; lapatinib with capecitabine requires prior anthracycline, taxane, and trastuzumab).
    Step therapy ruleRequirement
    Documentation of prior therapies
    Providers must submit documentation of current or previous therapies used to treat the condition when step therapy or prior‑therapy requirements apply; this includes dates, agents tried, and reason for discontinuation (failure or intolerance) where applicable.
    Step therapy ruleRequirement
    Document trials and reasons for failure/intolerance
    When step therapy is required, the request must include documentation of trials and clinical reasons for failure or intolerance to required prior therapies (e.g., inadequate response, adverse effects, contraindication).
    Step therapy ruleRequirement
    Prior trials documentation required
    Authorization requires documentation that the member tried and had inadequate response to, or was intolerant/contraindicated to, required prior therapies; examples include maximal inhaled therapy for mepolizumab or trials of two different classes for Inbrija.
    Step therapy ruleRequirement
    Required unless contraindicated
    Certain step‑therapy trials are required for initial authorization unless a contraindication or intolerance is documented (example: Inbrija requires trials of at least two different medication classes unless contraindicated).
    Step therapy ruleRequirement
    General required for initial authorization
    Many products require prior trial(s) of specified therapies before initial authorization; prescribers must attest prior therapies were tried and provide objective supporting documentation when requested (lab values, diagnostics, prior medication records).
    Step therapy ruleRequirement
    Antipsychotic prior trials
    Initial authorization for antipsychotics (e.g., schizophrenia, bipolar) requires documented trials and failures or intolerance to specified generic second‑generation antipsychotics (examples include aripiprazole and another generic agent); for Caplyta in bipolar depression, failure/intolerance to two listed alternatives is required.
    Step therapy ruleRequirement
    Prior trial of specified therapies from different classes
    Some indications require trials of therapies from different medication classes prior to approval (example: vasomotor symptom agents require failure of at least two prior systemic hormone or non‑hormonal therapies from different classes).
    Step therapy ruleRequirement
    Required prior/concurrent guideline background therapies
    For some disease states (e.g., HFrEF, PAH), prior or concurrent use of guideline‑recommended background therapies at maximally‑tolerated doses is required before authorization (examples: ACEi/ARB or sacubitril/valsartan, beta‑blocker, MRA for HFrEF; nitric oxide pathway mediator plus endothelin receptor antagonist for PAH).
    Step therapy ruleRequirement
    Voyxact prior‑use requirement
    For voyxact coverage (IgAN example), the patient must have tried and failed to have an adequate response to or been intolerant of maximally‑tolerated ACE inhibitor/ARB (and other specified agents where applicable) prior to initial authorization.
    Step therapy ruleRequirement
    Document prior trials and failures (general)
    For products with step therapy requirements, providers must document prior trials and failures or intolerance to specified therapies as described in product‑specific criteria (e.g., ZILBRYSQ, ZORYVE examples).

    Coverage by Site of Care (Part B vs Part D Considerations)

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy Scope and Background

    This document establishes prior authorization rules tied to clinical indications and requires submission of specific diagnostic confirmation, prescriber specialty, age limits, and exclusion checks before coverage is approved. Providers must submit required objective data (for example, hemodynamics for pulmonary hypertension, genetic or biomarker tests for mutation‑directed therapies, and baseline labs or ECG when QT risk is present) and attest to prior therapy trials when required. Failure to obtain prior authorization or to provide requested documentation (including pregnancy status for females of childbearing potential) may result in denial of coverage. Coverage durations are typically 1 year unless otherwise specified, and many agents are restricted to specialty prescribers per the policy.